"Tolerability remains an issue in the current treatment landscape of chronic lymphocytic leukaemia, which may require ongoing therapy for many years," Jeff Sharman, director of research at Willamette Valley Cancer Institute, medical director of Hematology Research for The US Oncology Network, and a lead author of the ELEVATE-TN trial, said in a press release.
"U dulqaadashada ayaa weli ah arrin ka jirta muuqaalka daaweynta ee hadda CLL, taas oo u baahan karta daaweyn socota sanado badan," ayuu yiri Jeff Sharman, MD, Agaasimaha Cilmi baarista ee Dooxada Willamette Kansarka Machadka, Agaasimaha Caafimaadka ee Cilmi-baarista Hematology ee Shabakada Oncology ee Mareykanka, iyo hogaamiyaha qoraaga tijaabada ELEVATE-TN, war-saxaafadeed.